牛牛AI助理已提取核心訊息
On February 21, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, along with other business highlights. The announcement included the approval of CASGEVY™ in multiple regions for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), and the progress of clinical trials for several product candidates, including CTX112™ and CTX131™ targeting CD19 and CD70, and in vivo gene editing candidates CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a). The company also reported on the ongoing clinical trial for CTX211™ for Type 1 Diabetes (T1D) treatment. CRISPR Therapeutics strengthened its balance sheet with a $280 million registered direct offering, bringing its current cash position to over $2.1 billion. The financial results showed a net income of $89.3 million for the fourth quarter of 2023, compared...Show More
On February 21, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, along with other business highlights. The announcement included the approval of CASGEVY™ in multiple regions for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), and the progress of clinical trials for several product candidates, including CTX112™ and CTX131™ targeting CD19 and CD70, and in vivo gene editing candidates CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a). The company also reported on the ongoing clinical trial for CTX211™ for Type 1 Diabetes (T1D) treatment. CRISPR Therapeutics strengthened its balance sheet with a $280 million registered direct offering, bringing its current cash position to over $2.1 billion. The financial results showed a net income of $89.3 million for the fourth quarter of 2023, compared to a net loss of $110.6 million for the same period in 2022. Cash, cash equivalents, and marketable securities were reported at $1,695.7 million as of December 31, 2023. The company's CEO, Samarth Kulkarni, Ph.D., expressed excitement for the upcoming year with a focus on continuing to innovate and execute clinical trials across various therapeutic areas.
2024年2月21日，生物製藥公司CRISPR Therapeutics AG公佈了截至2023年12月31日的年度財務業績以及其他業務亮點。該公告包括批准CASGEVY™ 在多個地區用於治療鐮狀細胞病（SCD）和輸血依賴性β地中海貧血（TDT），以及幾種候選產品的臨床試驗進展，包括針對CD19和CD70的 CTX112™ 和 CTX131™，以及靶向ANGPTL3 和Lp（a）的活體基因編輯候選藥CTX310™ 和 CTX320。™該公司還報告了正在進行的用於1型糖尿病（T1D）治療的 CTX211™ 臨床試驗。CRISPR Therapeutics通過2.8億美元的註冊直接發行加強了其資產...展開全部
2024年2月21日，生物製藥公司CRISPR Therapeutics AG公佈了截至2023年12月31日的年度財務業績以及其他業務亮點。該公告包括批准CASGEVY™ 在多個地區用於治療鐮狀細胞病（SCD）和輸血依賴性β地中海貧血（TDT），以及幾種候選產品的臨床試驗進展，包括針對CD19和CD70的 CTX112™ 和 CTX131™，以及靶向ANGPTL3 和Lp（a）的活體基因編輯候選藥CTX310™ 和 CTX320。™該公司還報告了正在進行的用於1型糖尿病（T1D）治療的 CTX211™ 臨床試驗。CRISPR Therapeutics通過2.8億美元的註冊直接發行加強了其資產負債表，使其目前的現金狀況超過21億美元。財務業績顯示，2023年第四季度的淨收入爲8,930萬美元，而2022年同期的淨虧損爲1.106億美元。截至2023年12月31日，現金、現金等價物和有價證券報告爲16.957億美元。該公司首席執行官薩瑪斯·庫爾卡尼博士對來年表示興奮，他專注於繼續創新和執行各個治療領域的臨床試驗。
有用
沒用
